Your session is about to expire
← Back to Search
ASTX660 for Cancer
Study Summary
This trial is testing a new drug, ASTX660, to see if it is safe and works well against cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My brain metastases are stable or have been treated.My cancer is advanced, cannot be surgically removed, and has no standard treatment options.My lymphoma is CD30-positive and I can't use or have already used brentuximab vedotin.I have mycosis fungoides or Sezary syndrome and cannot take mogamulizumab.I have HIV or active hepatitis B or C.I do not have severe nerve pain or damage.I have other serious health conditions besides my current illness.I do not have any severe illnesses or conditions that could risk my safety or affect the study results.I have a history of heart problems or am at risk for them.I can take care of myself and am up and about more than half of my waking hours.I am following the birth control requirements outlined in the study.My cancer can be measured by tests.My organ functions are within normal ranges according to recent tests.I haven't had cancer treatment within the required time before starting ASTX660.My disease is worsening and I've had at least two treatments before.I am 18 years old or older.My cancer is a specific type of lymphoma recognized by the WHO.
- Group 1: Phase 2 - Cohort 3
- Group 2: Phase 2 - Cohort 5
- Group 3: Phase 1 - Part 1 (completed)
- Group 4: Phase 1 - Part 3 (optional)
- Group 5: Phase 2 - Cohort 1
- Group 6: Phase 1 - Part 2 (completed)
- Group 7: Phase 2 - Cohort 2
- Group 8: Phase 2 - Cohort 4
- Group 9: Phase 2 - Cohort 6
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the enrollment capacity of this trial?
"This research trial has ceased recruitment as of November 18th 2022. It was initially posted on July 1st 2015 and is no longer accepting any more participants. However, for those looking for other trials related to lymphoma there are presently 2136 studies recruiting patients. Additionally, 3 clinical trials are currently enrolling individuals with ASTX660."
Is this research a pioneering effort for its field?
"To date, ASTX660 has been subject to 3 clinical trials in 43 cities and 9 countries. The earliest of these began in 2015 under the patronage of Astex Pharmaceuticals Inc., with 230 participants taking part over two stages. Since then, two further studies have concluded."
Are there any openings for volunteers to join this clinical trial?
"Clinicaltrials.gov states that this particular trial is no longer accepting patients, which was the case since its posting on July 1st 2015 and most recent update of November 18th 2022. However, there are 2139 other trials available for enrollment at this time."
What earlier research has been conducted utilizing ASTX660?
"In 2015, ASTX660 was initially investigated at Cancer Care Manitoba. Subsequently, there were two completed trials and presently three studies are seeking participants with a large proportion of them occurring in Oklahoma City."
How many medical institutions are administering this research experiment?
"This trial has been rolled out in 32 different sites, with notable locations such as the University of Oklahoma Stephenson Cancer Center located in Oklahoma City, University of Washington, Seattle Cancer Care Alliance based in Seattle, and Tom Baker Cancer Centre situated in Calgary."
What is the goal of this experiment?
"According to the trial sponsor, Astex Pharmaceuticals Inc., this evaluation aims to measure Efficacy (Phase 2) - antitumor activity assessed by disease control rate (DCR) during a period of up to 78 months. Secondary parameters such as Pharmacokinetic outcome of time to maximum concentration (Tmax), and assessment of ASTX660 metabolites if applicable, in addition to other secondary PK parameters will also be monitored."
Share this study with friends
Copy Link
Messenger